peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Medical strengthens its liquidity

3 Oct 2013, 16:30
Regulatory information
Hansa Medical has been granted a bank overdraft facility of SEK 5 million. The funds have been secured to ensure that the company can, with a good margin, complete and document the current Phase I study of the drug candidate, IdeS. The vision for the drug candidate IdeS is to facilitate kidney transplantation for patients with end stage kidney disease that are currently very difficult to transplant.

”We have secured this credit in order to concentrate entirely on the finalisation and reporting of the ongoing clinical Phase I study of IdeS. The Phase I study was initiated in March 2013 and our goal is to complete this study during the current year. We will, thereafter, aim at initiating the exciting Phase II study during the spring of 2014”, states Emanuel Björne, CEO of Hansa Medical AB.

Highly sensitized renal transplant patients
There are many requirements for a patient to actually be able to undergo a kidney transplant. The patients on the transplant wait lists include a sub-group of patients comprised of highly sensitized transplant patients. These patients’ immune systems are characterised by high levels of reactive antibodies significantly reducing the body’s possibility to receive a donated, healthy organ. A vast majority of these patients have to spend significantly longer time waiting for a transplant.

The drug candidate IdeS
The drug candidate IdeS inactivates antibodies immediately prior to a kidney transplant and, in this manner, removes this particular obstacle to transplantation. The goal is to be able to treat approximately 5,000 patients a year in the US and Europe, at a total value of slightly more than one billion SEK.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in Phase I trial, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.